QLP3119/PSB219 is a novel biological entity consisting of two humanized monoclonal antibodies: an anti-TSLP IgG1 and an anti-IL-33 IgG4. These antibodies are designed to target and inhibit two key proinflammatory cytokines thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33)—that play central roles in the pathogenesis of allergic inflammation associated with severe asthma and chronic obstructive pulmonary disease (COPD).
Developed using Sound Biologics’ proprietary MabPair platform, PSB219 is manufactured as a single drug substance in which both antibody components are produced together from one engineered cell line at a predefined ratio. By engaging both pathways, PSB219 can achieve broader and more durable suppression of airway inflammation than single-pathway blockade. Nonclinical studies demonstrated enhanced pharmacologic activity and a well-defined mechanism of action, supporting its advancement as a dual-specific biologic for respiratory inflammation.
Regulatory status: IND cleared for clinical studies by FDA in US and NMPA in China.
